It has also been reported that ECs harboring MLH1 hypermethylation showed poorer response to ICB therapy compared with Lynch syndrome-associated ECs, which implied the different immunotherapy response-associated genetic alternations may exist in etiologically distinct EC subgroups. Here, MLH1 is linked to Lynch syndrome.